Invitation biopartnering north america 2011 for life science nord

An die Cluster-Mitglieder
Life Science Nord
Sehr geehrte Damen und Herren,
ich möchte Sie gerne auf die BioPartnering North America™ vom 27. Februar bis 1. März im
kanadischen Vancouver hinweisen.
Als die führende Biotechnologie Partnering-Konferenz in Kanada wurde die BioPartnering North
America™ im letzten Jahr von über 800 Branchenvertretern aus über 26 Ländern besucht.
Informationen zur BioPartnering North America™ finden Sie unter
Wir bieten Ihnen an, schon im Vorfeld der BioPartnering North America die Möglichkeit zu Partnering-
mit potentiellen Kooperationspartnern aus wissenschaftlichen Institutionen in British
Columbia wahrzunehmen. Die Partnering-Gespräche werden dabei vor Ort nach Ihren Wünschen
durch die Kollegen im Ministry of Tourism, Trade and Investment der Regierung von British Columbia
Die kanadische Provinz British Columbia ist eine der am schnel sten wachsenden nordamerikanischen
Regionen auf dem Gebiet der roten Biotechnologie, mit Centres of Excellence wie PrioNet
(, The Ovarian Cancer Research Initiative (, Genome
British Columbia
(, The BC Cancer Agency ( und dem
Centre for Drug Research and Development ( Eine Übersicht über wissenschaftliche
Institute sowie Forschungsinitiativen in British Columbia entnehmen Sie bitte der beigefügten
Bei Interesse für die BioPartnering North America können Mitglieder des Clusters Life Science Nord
über das International Trade and Investment Representative Office des Government of British
kostenlose Konferenzpässe erhalten. Zudem gibt es noch einige 15 Minuten-Vortrags-
Die Anzahl der Pässe und der Vortragsmöglichkeiten ist begrenzt und werden nach dem “first come,
first serve“
Prinzip vergeben. Außerdem wird derzeit mit Hotels in Vancouver über besondere
Konditionen gesprochen.
Für Informationen und Rückfragen hierzu stehe ich Ihnen gerne jederzeit zur Verfügung.
Mit freundlichen Grüßen
Rainer M, Giersch
International Trade and Investment Representative Office Tel: +49 - 40 - 23 2288 - Fax: +49 - 40 - 23 2277 Red Life Science in British
Red Life Science in British Columbia
Supported by a strong foundation of world-class health research, a wealth of commercialization resources and ever more favourable political and economic conditions, British Columbia, Canada continues to develop a Red* Life Science cluster BC is fortunate to have and integrated network of leading researchers, state of the art facilities and institutions forming the basis for an industry that is developing a wide array of biopharmaceutical products and technologies. From novel activation and delivery of drugs to antisense enhancement of chemotherapy, BC stands at the forefront of The BC Red life science industry includes over 90 companies, representing the most developed sub-sector of BC’s overall life sciences industry. It is the seventh largest biopharmaceutical cluster in North America and employs over 2,200 people. It has also seen significant commercial success to date, generating revenue in the range of $800 million per year. By number of companies, BC’s biopharmaceutical sector is the fastest The global biopharmaceutical landscape is highly dynamic. Traditional pharmaceutical development aimed simply at symptom relief has evolved to focus on mechanism based approaches, disease modifying treatments, personalized medicine and healthcare efficiency. BC has managed to keep pace, and often to lead, this shift in innovation, feasible only with a vibrant, collaborative and supportive community. (* in the life sciences the colour red denotes: human health; blue: ocean; white: Leading Institutions and Centres of Excellence
British Columbia is home to strong, integrated network built around three leading Universities; The University of British Columbia, Simon Fraser University and The University of Victoria. Combined with a public healthcare delivery system originally based on a Scandinavian model, and nationally recognized and endorsed Centres of Excellence in a number of key areas, British Columbia offers tremendous capability and The BC Cancer Agency (BCCA) - - Canada’s and one of
the world’s leading cancer organizations, integrating research, healthcare delivery and innovative solutions to cancer prevention, care and treatment. The Brain Research Centre – a unique partnership
between Vancouver Coastal Health Research Institute and the Faculty of Medicine at the University of British Columbia. The hospital has combined forces with broad, multi disciplinary research expertise at the University of British Columbia to advance our knowledge of the brain and to explore new discoveries and technologies that have the potential to reduce the suffering and cost associated with disease and injuries of the brain. The International Collaboration on Repair Discoveries (ICORD) - - a UBC Research Centre that is focused on spinal cord injury (SCI). Our research platform includes two Research Programs, each of which span Discovery and Clinical Research: CURE— to accelerate the search for a cure for spinal cord injury, and QOL— to enhance the quality of life for people living with spinal cord injury. ICORD is located at the Blusson Spinal Cord Research Centre, the world’s largest, most advanced and most comprehensive facility devoted to spinal cord injury research and patient care. NeuroDevNet – - a Canada-wide Centre of Excellence
based at the University of British Columbia dedicated to the prevention and The Prostate Centre’s Translational Research Initiative for Accelerated
Discovery and Development (PC-TRIADD) - - PC-
TRIADD acts as a bridge between academia and the biotechnology and pharmaceutical industry to conduct pre-clinical and clinical proof-of-concept studies on projects originating in both academia and industry. Its primary focus is on the mechanisms of late stage tumour progression and acquired treatment resistance in prostate cancer. PC- TRIADD is under the direction of leading urologist and surgeon Dr. Martin Gleave, who also holds B.C.’s Leadership Chair in Prostate Cancer Research and is co-founder of BC-based biotech company and recent success story, OncoGenex Technologies; The Prevention of Epidemic Organ Failure (PROOF) – – a centre dedicated to finding practical solutions to vital organ failure and reducing organ failure’s impact on the health care system. PROOF's team of world-class researchers, scientists and clinicians are committed to improving the standard of care and quality of life for patients faced The Centre for Drug Research and Development – - CDRD
guides early-stage discoveries made by BC’s top academic and health researchers through the preclinical drug development process. CDRD’s expertise and facilities help researchers overcome obstacles to the overhead intensive, early development and testing of innovative pharmaceuticals towards bridging the gap between applied research and clinical testing. Advanced Applied Physics Solutions – - Canada's national
laboratory for research into particle and nuclear physics, AAPS’ mission is to commercialize advanced physics technologies for the social and economic well- being of Canadians and around the world. Few people recognize that physics innovation at TRIUMF has contributed to the health and biopharmaceutical fields of radio-labelled pharmaceuticals, radio-imaging technologies including positron emission tomography and proton treatment of certain types of ocular cancer. PrioNet is a Canadian Centre of Excellence – -
PrioNet's goals are to develop strategies to mitigate, and ultimately eradicate, prion diseases. Prion diseases are fatal, transmissible, and untreatable diseases of humans and animals associated with a sponge-like degeneration of brain tissue caused by rogue proteins called prions. They include chronic wasting disease in deer and elk, bovine spongiform encephalopathy (BSE, or mad cow disease), Creutzfeldt-Jakob disease in humans and others. The Centre for Hip Health and Mobility – - The Centre is
committed to enhance the prevention, detection and treatment of bone and joint problems affecting the hip. Research carried out at the Centre covers the lifespan, from primary prevention programs for children to early detection of disease in adults, intervention programs for the at-risk elderly and improved The Ovarian Cancer Research Initiative – - The centre is
focused on three specific goals. The first is to improve ovarian cancer survival through early detection of disease. OvCaRe researchers are working to identify proteins that are produced in the early stages of ovarian cancer. Detection of these proteins can then be developed into diagnostic tests to allow for earlier diagnosis of ovarian cancer. The second goal is to develop new therapies for ovarian cancer treatment. This is being achieved through research aimed at identifying the cause of ovarian cancer at the cellular level and then directly and specifically targeting that defect. OvCaRe is using a similar strategy to develop treatments to prevent ovarian cancer recurrence. The third goal of OvCaRe is to develop individualized ovarian cancer treatments. Genome British Columbia - - is a leading institution focused
on the support of research and innovation in all areas of the life sciences that has The Michael Smith Foundation for Health Research (MSFHR) - - is one of BC’s key funding bodies for research and collaboration Complimenting BC’s wealth in research and discovery, the simultaneous emergence of a business environment readily enabling the translation of research into commercial success has produced great value in BC for global partners and investors. In this context, the majority of B.C.’s biopharmaceutical companies formed as spin-offs from these public research institutions, and have been nurtured by researchers and business leaders with significant, relevant expertise, passion and entrepreneurial spirit. Vancouver is home to about 70% of the BC’s Red Life Science industry, including two of Canada’s largest and most successful biopharmaceutical companies: QLT and Recent collaborative, partnership and licensing successes include: Cardiome Pharmaceuticals - - with Merck - valued at up
to $1 billion, this deal for commercial rights to Cardiome’s drug for treating acute arterial fibrillation represents the largest licensing deal ever done in Canada;
Merger of OncoGeneX - - with Sonus Pharmaceuticals
resulting in a NASDAQ public listing and, combined with promising clinical results, produced a tenfold increase in OncoGenex’s market capitalization; Takeda Pharmaceuticals - - with Alnylam and subsequently
with Roche – Alnylam has partnered with Tekmira to deliver its RNAi
therapeutics to specific tissues. Roche, recognizing the opportunity of these combined technologies, partnered with Tekmira in a potential $34 million joint development transaction;
Xenon Pharmaceuticals - - with Roche, Novartis,
MERCK and Takeda. Xenon has built an impressive and strongly capitalized
research business based on world-class genomics and drug development know- how. Alongside a novel pain therapeutic program in early clinical development and partnered with Japanese pharmaceutical giant Takeda, Xenon is leveraging its gene based drug discovery expertise in anaemia and cardiovascular research programs with Roche and Merck, respectively. Strategic successes in BC’s biotechnology sector include the following acquisitions together valued at greater than $5.5 billion:
Aspreva Pharmaceuticals by the Galenica Group (October 2007, $915
million); and
Anormed Pharmaceuticals by Genzyme; (October 2006, $580 million)
ID Biomedical by GlaxoSmithKline (December 2005, $1.7 billion).
Abgenix Pharmaceuticals by Amgen (December 2005, $2.2 billion),
Additional innovative companies in BC’s biopharmaceutical space with promising technologies still in development are as follows: Allon Therapeutics - - Allon is a post Phase II,
clinical-stage biotechnology company developing the first, disease modifying drugs impacting the progression of neurodegenerative diseases. Allon’s drug Davunetide has demonstrated human efficacy in amnesic mild cognitive impairment, a precursor to Alzheimer’s disease, and schizophrenia-related Imimex Pharmaceuticals - - Inimex is a clinical stage
company focused on the development and commercialization of Innate Defense Regulators (IDRs) which are novel, first in class biological drugs that selectively trigger the body's innate defences without causing inflammation. Aquinox Pharmaceuticals - - Aquinox is developing
novel and targeted small molecule therapeutics for the treatment of cancer and inflammatory disease. Aquinox’s founders discovered a novel drug target, known as SHIP, and drugs to regulate this enzyme. Activation of SHIP inhibits the critical PI3K pathway which promotes cell growth, proliferation, survival, and immune activation of certain blood cells. MSI Methylation Sciences MSI has patented a new formulation of a
ubiquitously present, naturally occurring human molecule called S-Adenosyl Methionine (SAMe). SAMe has been produced and sold as a prescription drug in parts of Europe and as a dietary supplement in the US for more than 10 years. In physician trials, it is equally as effective as current antidepressant drug therapy (i.e. Prozac) but is free of some of the most intolerable side effects. In Summary
With its proven strategy, a successful track record and an unparalleled quality of life, it’s easy to see why the global biopharmaceutical sector is turning its attention to British In short, British Columbia’s magic is based on having all the right ingredients for Consistent value creation, presenting a high return on investment; Internationally top rated quality of life. The resulting possibilities in British Columbia’s Red Life Science industry are truly vast and we welcome your involvement and participation.


Please fill out this questionnaire and e-mail or fax it to:

SPLENECTOMY REGISTRY Intercontinental Cooperative ITP Study Group Please fill out this questionnaire and e-mail it to: Postfach CH-4031 Basel, Switzerland FAX: +41 61 704 12 41 History of ITP before splenectomy 1. 2. Diagnostic procedures and therapy before splenectomy 3. Bleeding signs at admission for splenectomy

Microsoft word - stanley.doc

International Learn to Swim Programme Resource Manual ILSP Assessment Standards – STAnley Stanley 1 - Learning outcomes Stanley 1 - Assessment Standards Be able to point to or name the teacher. Use ladder, platform ramp or swivel or assisted sitting entry. 3. Splash the feet on the surface, whilst holding the Stretch body across the water, move the water with the rail, troug

Copyright © 2014 Articles Finder